{"filing":{"accession_number":"0001453687-26-000105","cik":"0001453687","ticker":"RNAC","company_name":"Cartesian Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"rnac-20260929.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/rnac-20260929.htm"},"events":[{"id":35592,"run_id":32791,"accession_number":"0001453687-26-000105","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cartesian Therapeutics announced positive Phase 2 retreatment data for Descartes-08 in myasthenia gravis patients, demonstrating sustained clinical efficacy with a mean MG-ADL reduction of 6.6 points at Month 12 post-retreatment and a favorable safety profile with no new safety signals. This clinical milestone is material to investor assessment of the company's lead asset development trajectory as it approaches Phase 3 AURORA topline results expected in 1Q27.","company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39694,"accession_number":"0001453687-26-000105","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses positive Phase 2 retreatment data for Descartes-08 in myasthenia gravis patients, showing sustained clinical improvements and a favorable safety profile. While this is clinical trial progress rather than a traditional earnings release, earnings announcement, or other specifically enumerated event type, it represents material operational/clinical milestone information that would affect a reasonable investor's assessment of the company's lead asset development trajectory and regulatory pathway toward Phase 3 readout expected in 1Q27.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:34:41.353601+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39695,"accession_number":"0001453687-26-000105","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cartesian announced positive Phase 2 retreatment data for Descartes-08 in myasthenia gravis patients, showing sustained efficacy (mean MG-ADL reduction of 6.6 points at Month 12 post-retreatment) and a favorable safety profile with no new safety signals. This is a clinical trial milestone disclosure that would materially affect investor assessment of the company's lead asset development progress, particularly as the company approaches Phase 3 AURORA topline results expected in 1Q27. While this is clinical data rather than a traditional earnings release or M\u0026A event, it represents a significant operational/clinical milestone for a late-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:34:41.353601+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39694,"accession_number":"0001453687-26-000105","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses positive Phase 2 retreatment data for Descartes-08 in myasthenia gravis patients, showing sustained clinical improvements and a favorable safety profile. While this is clinical trial progress rather than a traditional earnings release, earnings announcement, or other specifically enumerated event type, it represents material operational/clinical milestone information that would affect a reasonable investor's assessment of the company's lead asset development trajectory and regulatory pathway toward Phase 3 readout expected in 1Q27.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:34:41.353601+00:00","company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","filing_date":"2026-09-29"},{"id":39695,"accession_number":"0001453687-26-000105","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cartesian announced positive Phase 2 retreatment data for Descartes-08 in myasthenia gravis patients, showing sustained efficacy (mean MG-ADL reduction of 6.6 points at Month 12 post-retreatment) and a favorable safety profile with no new safety signals. This is a clinical trial milestone disclosure that would materially affect investor assessment of the company's lead asset development progress, particularly as the company approaches Phase 3 AURORA topline results expected in 1Q27. While this is clinical data rather than a traditional earnings release or M\u0026A event, it represents a significant operational/clinical milestone for a late-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:34:41.353601+00:00","company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","filing_date":"2026-09-29"}]}